Adamas PD candidate nears NDA

Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) said ADS-5102 met the primary endpoint in the Phase III EASE LID 3 study to treat levodopa-induced dyskinesia (LID) in Parkinson's disease patients. Compared with placebo, the candidate led to significantly greater reductions in Unified Dyskinesia Rating Scale (UDysRS) total scores at week 12 (46% vs. 16%; p<0.0001). The company plans to submit an NDA for the oral extended-release formulation of amantadine this year.

In December 2015, the company said ADS-5102 met the Phase III EASE LID study's primary endpoint (see BioCentury Extra, Dec. 23, 2015). ...